Company Overview and News

5
Sensex hits fresh record high on firm global cues

2018-07-13 freepressjournal.in
Mumbai: The BSE Sensex hit a fresh record high of 36,740.07 points in opening session today driven by smart gains in Infosys, Coal India and Wipro, despite weak macroeconomic data released yesterday.
500820 500469 FEDA ASIANPAINT 533278 500470 532187 532461 FEDS HDFCBANK 500570 FEDERALBNK TATAMOTORS CLNDY SBAZ INDUSINDBK FDBAY TTST PNJZY TATASTEEL TATLY HDB 500180 PNB COALINDIA TTM

0
Sensex, Nifty turn choppy on weak Asian cues

2018-07-11 freepressjournal.in
Mumbai: The benchmark BSE Sensex opened 59.64 points higher, but soon turned choppy in early trade, as investors cashed profits in metal, healthcare, PSU and auto stocks, amid weak Asian cues as US-China trade spat escalated.
BAJAJ-AUTO YESBANK 500820 AXB INDUSINDBK 532648 YYBKY 532977 ASIANPAINT 533278 532215 AXBKY AXBA 532187 AXISBANK CLNDY COALINDIA

0
Podcast | An evening walk down Dalal Street: Good News! Sensex just 200 points away from record highs

2018-07-10 moneycontrol
Bulls took charge of D-Street from the word go and pushed the S&P BSE Sensex above 36,000 on Tuesday and is now just 204 points short of its record high of 36,443.98 recorded on 29 January 2018.
BAJAJ-AUTO 500825 590021 500408 500325 500820 BNPQY RELIANCE 539336 BRTQY HCTHY 532977 533179 ASIANPAINT 533278 532187 BHARATRAS RIGD 532281 BRITANNIA CLNDY 509488 RLNIY YESBANK GRAPHITE INDUSINDBK KMBKY 532648 AEGISLOG YYBKY BNPQF BNPZY GUJGAS HCLTECH KOTAKBANK 500003 TATAELXSI 500247 COALINDIA PERSISTENT

0
An evening walk down Dalal Street: Global cues lift Sensex 277 pts ahead of Q1FY19 earnings

2018-07-09 moneycontrol
Equity benchmarks began the week on a strong note on Monday, gaining over 0.70 percent on positive global cues and ahead of June quarter earnings. Banks and metals stocks, and Reliance Industries, L&T and Infosys drove the market higher.
DB 500325 500820 JIPKY RELIANCE KTKBANK 532538 ASIANPAINT 532187 505283 RIGD UCLQY 500493 BHARATFORG RLNIY YESBANK INDUSINDBK KIRLPNU JPASSOCIAT UCLQF 532648 YYBKY STRTECH ULTRACEMCO 532532 SRLRY 532652 532374

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

21h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

23h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...